Novadip NVD003
Autologous cell therapy for congenital pseudarthrosis of the tibia
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
NVD003 is Novadip’s autologous cell-based regenerative therapy candidate for congenital pseudarthrosis of the tibia, advancing through pivotal Phase 3 clinical studies in the United States and Europe.
- Website
- novadip.com/pipeline
- Added via
- web
- Ownership
- unclaimed
Where to go
Product details
- Product kind
- Other